Meeting
2019 Gastrointestinal Cancers Symposium
Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO.
Authors
Thomas Jens Ettrich
Ulm University, Ulm, Germany
Thomas Jens Ettrich , Andreas Wolfgang Berger , Thomas Decker , Ralf Hofheinz , Volker Heinemann , Thomas Hoffmann , Holger Frithjof Hebart , Thomas Herrmann , Carla Verena Hannig , Petra Buechner-Steudel , Melanie Guethle , Hanna Bartholomaeus , Alica Beutel , Lukas Perkhofer , Thomas Seufferlein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01362361
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 666)
DOI
10.1200/JCO.2019.37.4_suppl.666
Abstract #
666
Poster Bd #
M11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2013 ASCO Annual Meeting
Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment.
First Author: Thomas Hoehler
Poster
2013 Gastrointestinal Cancers Symposium
A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808).
First Author: Hiroyuki Uetake
Poster
2012 ASCO Annual Meeting
TRICC-c: BIBF 1120 versus placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)—A multicenter, randomized phase II trial in progress.
First Author: Andreas Berger